EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieÄquivalenzstudie

Fourteen‐Day Tegoprazan–Amoxicillin Dual Therapy as the First‐Line Treatment of Helicobacter pylori Infection ( SHARE2301 ): A Multicenter, Noninferiority, Randomized Clinical Trial

Qingzhou Kong iD, Iqtida Ahmed Mirza, Xiaoqian Zhang, Xiaohui Song, Xiaowei Li, Qiumei Zhang, Lidong Xu, Yuting Guo, Yanan Yu, Xiuli Zuo iD, Yanqing Li iD, Yueyue Li iD

Helicobacter · 2024-05 · 29 (3)

DOI: 10.1111/hel.13098 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Helicobacter, online erschienen am 09.06.2024. Verfasst von Qingzhou Kong und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Amoxicillin, Helicobacter pylori, Anti-Bacterial Agents. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Key Technology Research and Development Program of Shandong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Potassium‐competitive acid blockers have demonstrated enormous potential in the eradication treatment of Helicobacter pylori infection, with tegoprazan being one of the representatives. The available data on the safety and efficacy of tegoprazan in dual therapy are limited. Materials and Methods The multicenter, noninferiority, randomized‐controlled trial was conducted from May 2023 to March 2024. Treatment‐naive subjects were randomly assigned (1:1) to enter either the tegoprazan–amoxicillin (TA) group (tegoprazan 50 mg twice daily and amoxicillin 750 mg four times daily) or the esomeprazole–amoxicillin (EA) group (esomeprazole 20 mg and amoxicillin 750 mg all four times daily), with a duration for 14 days. The primary outcome was eradication rate as determined by 13 C‐urea breath test, including per‐protocol (PP) analysis and intention‐to‐treat (ITT) analysis. Secondary outcomes were adverse events and compliance.

Results

A total of 368 individuals were included in the randomization. The eradication rates in the EA group and the TA group were 84.2% and 85.8%, respectively, according to an ITT analysis ( p = 0.77), and 88.5% and 88.2%, respectively, according to PP analysis ( p = 1.00). The eradication rates for the TA group were not inferior to those of the EA group in both PP ( p = 0.0023) and ITT analyses ( p = 0.0009). There were no significant statistical differences in the incidence of adverse events and compliance between the two groups. The multivariate logistic regression analysis revealed that poor compliance increased the risk of eradication failure ( p < 0.001).

Conclusions

Dual therapy containing tegoprazan is safe and effective to be considered as a clinical first‐line treatment option, but further optimization involving antimicrobial susceptibility testing and adjustments in dosage and frequency is warranted. Trial Registration ClinicalTrials.gov ID: NCT05870683.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsAmoxicillinHelicobacter pyloriAnti-Bacterial AgentsDrug Therapy, CombinationHumansMaleFemaleMiddle AgedAdultTreatment OutcomeProton Pump InhibitorsAgedBreath TestsEsomeprazolePyrrolesSulfonamides

Stichwörter der Autor:innen

Helicobacter pyloriefficacyeradicationsafetytegoprazan

Substanzen

AmoxicillinAnti-Bacterial AgentsProton Pump Inhibitors1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineEsomeprazolePyrrolesSulfonamides

Autor:innen und Institutionen

  • Department of Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Laboratory of Translational Gastroenterology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Shandong Provincial Clinical Research Center for Digestive Disease, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Department of Gastroenterology, Shandong Second Medical University Affiliated Hospital, Weifang, Shandong, China.
  • Department of Gastroenterology, The People's Hospital of Jimo, Qingdao, Shandong, China.
  • Department of Gastroenterology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, Shandong, China.

ORCID-Profile: Qingzhou Kong, Xiuli Zuo, Yanqing Li, Yueyue Li

Förderung

  • Key Technology Research and Development Program of Shandong Province
  • National Natural Science Foundation of China

Zitieren

APA

Kong, Q., Mirza, I. A., Zhang, X., Song, X., Li, X., Zhang, Q., Xu, L., Guo, Y., Yu, Y., Zuo, X., Li, Y., & Li, Y. (2024). Fourteen‐Day Tegoprazan–Amoxicillin Dual Therapy as the First‐Line Treatment of Helicobacter pylori Infection ( SHARE2301 ): A Multicenter, Noninferiority, Randomized Clinical Trial. Helicobacter, 29(3). https://doi.org/10.1111/hel.13098

Vancouver

Kong Q, Mirza IA, Zhang X, Song X, Li X, Zhang Q, et al. Fourteen‐Day Tegoprazan–Amoxicillin Dual Therapy as the First‐Line Treatment of Helicobacter pylori Infection ( SHARE2301 ): A Multicenter, Noninferiority, Randomized Clinical Trial. Helicobacter. 2024;29(3). doi:10.1111/hel.13098

BibTeX
@article{Kong2024,
  author = {Kong, Qingzhou and Mirza, Iqtida Ahmed and Zhang, Xiaoqian and Song, Xiaohui and Li, Xiaowei and Zhang, Qiumei and Xu, Lidong and Guo, Yuting and Yu, Yanan and Zuo, Xiuli and Li, Yanqing and Li, Yueyue},
  title = {Fourteen‐Day Tegoprazan–Amoxicillin Dual Therapy as the First‐Line Treatment of Helicobacter pylori Infection ( SHARE2301 ): A Multicenter, Noninferiority, Randomized Clinical Trial},
  journal = {Helicobacter},
  year = {2024},
  volume = {29},
  number = {3},
  doi = {10.1111/hel.13098}
}
Kostenlos starten →